This notice does not concern the award of a public contract within the meaning of the procurement coordination directive (2014/24 / EU) or antitrust law. In order to provide the widest possible information to interested pharmaceutical companies, this notice is published in the Supplement to the Official Journal of the European Union. The procedure "open procedure" (section IV.1.1) used in this notice is due to the requirements of the Notice Form. Hereby, as well as with the use of the medium "TED", no submission is subject to procurement regulations whose validity is not prescribed by law or public procurement regulations. It is a framework contract with accession option, which refers to various active ingredients.
The subject of the agreement are medicinal products containing the active substance adalimumab.
The subject of the agreement are medicinal products containing the active ingredient combination fusidic acid and betamethasone valerate.
The subject of the agreement is medicinal products containing the active substance iloprost.
The subject of the agreement is medicinal products containing the active substance imiquimod.
The subject of the agreement are medicaments containing the active substance mebeverine in a retarded oral dosage form.
Subject of the agreement are medicines containing the active substance mitomycin.
The subject of the agreement is medicinal products containing the active substance natalizumab.
Subject of the agreement are medicines containing the active substance peginterferon beta-1a.
The subject of the agreement is medicinal products containing the active substance piroxicam.
The subject of the agreement is medicinal products containing the active substance raloxifene.
The subject of the agreement is medicaments containing the active substance salbutamol in the dosage form inhalable powder.
The subject of the agreement is medicinal products containing the active substance ambrisentan.
Subject of the agreement are medicines containing the active substance sirolimus.
The subject of the agreement is medicines containing the active substance tacrolimus in a dermal dosage form.
The subject of the agreement are medicinal products containing the active substance ulipristal in potency of 5 mg.
The subject of the agreement are medicinal products containing the active ingredient combination omeclidinium cation and vilanterol.
The subject of the agreement is medicines containing the active substance aprepitant.
The subject of the contract is medicinal products containing the active substance bexarotene.
The subject of the agreement is medicinal products containing the active substance cefadroxil.
The subject of the agreement is medicaments containing the active substance diclofenac in a dermal dosage form.
The subject of the agreement is medicinal products containing the active substance fentanyl in an oral, divided dosage form.
The subject of the agreement are medicinal products containing the active ingredient combination fluticasone furoate and vilanterol.
The subject of the agreement are medicinal products containing the active ingredient combination formoterol and fluticasone 17-propionate.